177 related articles for article (PubMed ID: 37909991)
1. Renal Cell Cancer - Insights in Drug Resistance Mechanisms.
Aweys H; Lewis D; Sheriff M; Rabbani RD; Lapitan P; Sanchez E; Papadopoulos V; Ghose A; Boussios S
Anticancer Res; 2023 Nov; 43(11):4781-4792. PubMed ID: 37909991
[TBL] [Abstract][Full Text] [Related]
2. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
3. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
Figlin RA; Kaufmann I; Brechbiel J
Int J Cancer; 2013 Aug; 133(4):788-96. PubMed ID: 23319457
[TBL] [Abstract][Full Text] [Related]
4. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
6. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
7. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.
Santoni M; Pantano F; Amantini C; Nabissi M; Conti A; Burattini L; Zoccoli A; Berardi R; Santoni G; Tonini G; Santini D; Cascinu S
Biochim Biophys Acta; 2014 Apr; 1845(2):221-31. PubMed ID: 24480319
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
9. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
Sharma R; Kadife E; Myers M; Kannourakis G; Prithviraj P; Ahmed N
J Exp Clin Cancer Res; 2021 Jun; 40(1):186. PubMed ID: 34099013
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.
Sekino Y; Teishima J; Liang G; Hinata N
Int J Urol; 2022 Dec; 29(12):1419-1428. PubMed ID: 36122306
[TBL] [Abstract][Full Text] [Related]
11. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
12. Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition.
Saliby RM; Saad E; Labaki C; Xu W; Braun DA; Viswanathan SR; Bakouny Z
Hematol Oncol Clin North Am; 2023 Oct; 37(5):1015-1026. PubMed ID: 37385938
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI-Resistant Metastatic Clear Cell Renal Cell Carcinoma.
Jeong SU; Hwang HS; Park JM; Yoon SY; Shin SJ; Go H; Lee JL; Jeong G; Cho YM
Cancer Res Treat; 2023 Jan; 55(1):231-244. PubMed ID: 35240013
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.
Sager RA; Backe SJ; Ahanin E; Smith G; Nsouli I; Woodford MR; Bratslavsky G; Bourboulia D; Mollapour M
Nat Rev Urol; 2022 May; 19(5):305-320. PubMed ID: 35264774
[TBL] [Abstract][Full Text] [Related]
16. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
17. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development.
Rasmussen N; Rathmell WK
Curr Clin Pharmacol; 2011 Aug; 6(3):199-206. PubMed ID: 21470103
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Kozłowski W; Szczylik C
Ann Oncol; 2015 Jul; 26(7):1385-9. PubMed ID: 25962440
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC.
Yadav RP; Chatterjee S; Chatterjee A; Pal DK; Ghosh S; Acharya K; Das M
J Recept Signal Transduct Res; 2022 Dec; 42(6):599-607. PubMed ID: 36125981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
